View Filing Data

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2015	Feb. 29, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Stereotaxis, Inc.
Entity Filer Category	Smaller Reporting Company
Entity Central Index Key	0001289340
Trading Symbol	stxs
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Amendment Flag	false
Document Type	10-K
Document Fiscal Period Focus	FY
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2015
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		21,622,856
Entity Public Float			$ 27.7

Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 5,593,582	$ 7,270,301
Accounts receivable, net of allowance of $93,478 and $131,464 in 2015 and 2014, respectively	6,376,470	6,480,499
Inventories	4,504,282	6,371,903
Prepaid expenses and other current assets	785,211	1,094,837
Total current assets	17,259,545	21,217,540
Property and equipment, net	1,067,321	894,728
Intangible assets, net	635,889	1,379,653
Other assets	264,159	388,850
Total assets	19,226,914	23,880,771
Current liabilities:
Accounts payable	1,840,135	2,353,133
Accrued liabilities	6,058,390	5,259,694
Deferred revenue	7,445,935	6,658,170
Warrants and debt conversion features	794,130	2,134,187
Total current liabilities	16,138,590	16,405,184
Long-term debt	18,429,177	18,388,764
Long-term deferred revenue	2,009,198	976,165
Other liabilities	275,603	660,376
Total liabilities	36,852,568	36,430,489
Stockholders' deficit:
Preferred stock, par value $0.001; 10,000,000 shares authorized, none outstanding at 2015 and 2014
Common stock, par value $0.001; 300,000,000 shares authorized, 21,551,173 and 20,480,874 shares issued at 2015 and 2014, respectively	21,551	20,481
Additional paid in capital	448,517,472	446,241,703
Treasury stock, 4,015 shares at 2015 and 2014	(205,999)	(205,999)
Accumulated deficit	(465,958,678)	(458,605,903)
Total stockholders' deficit	(17,625,654)	(12,549,718)
Total liabilities and stockholders' deficit	$ 19,226,914	$ 23,880,771

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Accounts receivable, allowance	$ 93,478	$ 131,464
Stockholders' deficit:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	21,551,173	20,480,874
Treasury stock, shares	4,015	4,015

Statements Of Operations - USD ($)	12 Months Ended
Statements Of Operations - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Revenue:
Systems	$ 10,640,584	$ 7,839,006
Disposables, service and accessories	27,033,940	27,172,270
Total revenue	37,674,524	35,011,276
Cost of revenue:
Systems	6,052,241	4,204,719
Disposables, service and accessories	4,385,917	4,018,661
Total cost of revenue	10,438,158	8,223,380
Gross margin	27,236,366	26,787,896
Operating expenses:
Research and development	6,252,791	5,158,331
Sales and marketing	15,850,362	15,168,940
General and administrative	10,543,741	11,845,289
Total operating expenses	32,646,894	32,172,560
Operating loss	(5,410,528)	(5,384,664)
Other income	1,340,057	3,510,439
Interest income	1,864	7,084
Interest expense	(3,284,168)	(3,335,300)
Net loss	$ (7,352,775)	$ (5,202,441)
Net loss per common share:
Basic	$ (0.35)	$ (0.26)
Diluted	$ (0.35)	$ (0.26)
Weighted average shares used in computing net loss per common share:
Basic	21,113,203	19,945,038
Diluted	21,113,203	19,945,038

Statements Of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Balance, Amount at Dec. 31, 2013	$ 19,311	$ 441,888,155	$ (205,999)	$ (453,403,462)	$ (11,701,995)
Balance, Shares at Dec. 31, 2013	19,311,390
Issuance of common stock and warrants, Amount	$ 879	2,852,794			2,853,673
Issuance of common stock and warrants, Shares	878,077
Share-based compensation		1,501,045			1,501,045
Grant of restricted shares, net of forfeitures, Shares	259
Restricted stock vestings, Amount	$ 291	(291)
Restricted stock vestings, Shares	291,148
Net loss				(5,202,441)	(5,202,441)
Balance, Amount at Dec. 31, 2014	$ 20,481	446,241,703	(205,999)	(458,605,903)	(12,549,718)
Balance, Shares at Dec. 31, 2014	20,480,874
Issuance of common stock and warrants, Amount	$ 809	940,545			941,354
Issuance of common stock and warrants, Shares	809,822
Share-based compensation		1,312,319			1,312,319
Restricted stock vestings, Amount	$ 242	(242)
Restricted stock vestings, Shares	241,775
Net loss				(7,352,775)	(7,352,775)
Employee stock purchase plan, Amount	$ 19	23,147			23,166
Employee stock purchase plan, Shares	18,702
Balance, Amount at Dec. 31, 2015	$ 21,551	$ 448,517,472	$ (205,999)	$ (465,958,678)	$ (17,625,654)
Balance, Shares at Dec. 31, 2015	21,551,173

Statements Of Cash Flows - USD ($)	12 Months Ended
Statements Of Cash Flows - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net loss	$ (7,352,775)	$ (5,202,441)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	320,301	413,773
Amortization of intangibles	299,833	299,833
Amortization of deferred finance costs	222,682	240,601
Share-based compensation	1,312,319	1,501,045
Impairment of intangible asset	443,931
Loss on asset disposal	5,883
Adjustment of warrants	(1,340,057)	(3,510,439)
Changes in operating assets and liabilities:
Accounts receivable	104,029	1,098,084
Inventories	1,521,995	(1,492,864)
Prepaid expenses and other current assets	86,944	144,518
Other assets	124,691	110,763
Accounts payable	(512,998)	(1,159,206)
Accrued liabilities	798,696	(1,634,850)
Deferred revenue	1,820,798	(376,499)
Other liabilities	(384,773)	475,539
Net cash used in operating activities	(2,528,501)	(9,092,143)
Cash flows from investing activities
Purchase of equipment	(153,151)	(123,912)
Net cash used in investing activities	(153,151)	(123,912)
Cash flows from financing activities
Proceeds (payments) from Healthcare Royalty Partners debt	40,413	(142,447)
Proceeds from issuance of stock and warrants, net of issuance costs	964,520	2,853,673
Net cash provided by financing activities	1,004,933	2,711,226
Net increase (decrease) in cash and cash equivalents	(1,676,719)	(6,504,829)
Cash and cash equivalents at beginning of period	7,270,301	13,775,130
Cash and cash equivalents at end of period	5,593,582	7,270,301
Supplemental disclosures of cash flow information:
Interest paid	$ 2,974,345	$ 3,028,884

Description Of Business	12 Months Ended
Description Of Business	Dec. 31, 2015
Description Of Business [Abstract]
Description Of Business	1. Description of Business Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional, procedures. The Epoch Solution is comprised of the Niobe ES Remote Magnetic Navigation System (“Niobe ES system”), Odyssey Information Management Solution (“Odyssey Solution”), and the Vdrive Robotic Navigation System (“Vdrive system”), and related devices. The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema, which is an innovative solution delivering synchronized content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation and training. Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems. We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. The core components of Stereotaxis systems, such as Niobe system, Odyssey Solution, Cardiodrive and various disposable interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries. We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the Vdrive and Vdrive Duo systems with the V-CAS, V-Loop and V-Sono devices in the U.S., Canada and European Union. Since our inception, we have generated significant losses. As of December 31, 2015, we had incurred cumulative net losses of approximately $466.0 million. In May 2011, the Company introduced the Niobe ES system and as of December 31, 2015, the Company had an installed base of 125 Niobe ES systems. In 2016, the Company plans to continue developing the Niobe ES system with the goal of furthering clinical adoption. Between 2011 and 2015, the Company implemented a wide ranging plan to rebalance and reduce operating expenses by 15% to 20% on an annual run rate basis. We expect to incur additional losses into 2016 as we continue the development and commercialization of our products, conduct our research and development activities and advance new products into clinical development from our existing research programs and fund additional sales and marketing initiatives. During 2016, we will continue to monitor operating expenses and make additional investment in certain targeted areas. We may be required to raise capital or pursue other financing strategies to continue our operations. Until we can generate significant cash flow from our operations, we expect to continue to fund our operations with cash resources primarily generated from the proceeds of our past and future public offerings, private sales of our equity securities and working capital and equipment financing loans. In the future, we may finance cash needs through the sale of other equity securities or non-core assets, strategic collaboration agreements, debt financings or through distribution rights. We cannot accurately predict the timing and amount of our utilization of capital, which will depend on a number of factors outside of our control. Our existing cash, cash equivalents and borrowing facilities may not be sufficient to fund our operating expenses and capital equipment requirements through the next 12 months, which would require us to obtain additional financing before that time. Further, our revolving line of credit with Silicon Valley Bank matures on March 31, 2018 subject to continuing compliance with our covenants. We cannot assure you that additional financing will be available on a timely basis on terms acceptable to us or at all, that we will be able to engage in equity financings if our common stock is delisted from NASDAQ, or that such financing will not be dilutive to our stockholders. If adequate funds are not available to us, we could be required to delay development or commercialization of new products, to license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize ourselves or to reduce the sales, marketing, customer support or other resources devoted to our products, any of which could have a material adverse effect on our business, financial condition and results of operations. In addition, we could be required to cease operations. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability of assets or the amounts of liabilities that may result should the Company be unable to continue as a going concern.

Summary Of Significant Accounting Policies	12 Months Ended
Summary Of Significant Accounting Policies	Dec. 31, 2015
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2. Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No cash was restricted at December 31, 2015 or 2014. Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators. Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 12 for disclosure of fair value measurements. Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items. Property and Equipment Property and equipment consist primarily of leasehold improvements, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years. Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs. Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates. Revenue and Costs of Revenue The Company adopted Accounting Standards Update 2009-13, Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”) in the fourth quarter of 2009, effective as of January 1, 2009. ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred. Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic alliances under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2015 or 2014 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned. Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date. The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares and units granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments. Shares purchased by employees under the 2009 Employee Stock Purchase Plan are considered to be non-compensatory. Net Earnings (Loss) per Common Share Basic earnings (loss) per common share are computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed by dividing the earnings (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. In addition, the application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable because the Company’s unearned restricted shares do not contractually participate in its losses. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2015, the Company had 706,494 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $9.34 per share and 2,120,365 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $4.82 per share. The Company had no unearned restricted shares outstanding for the period ended December 31, 2015. Income Taxes In accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized. Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate. Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. Biosense Webster Inc. accounted for $3,514,897 and $4,651,490, or 9%, and 13%, of total net revenue for the years ended December 31, 2015, and 2014, respectively. No other single customer accounted for more than 10% of total revenue for the year ended December 31, 2015. Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses. Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 - Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update. In November 2015, the FASB issued Accounting Standards Update (“ASU” or “Update”) No. 2015-17, “Income Taxes (Topic 740): To simplify the presentation of deferred income taxes”. The amendments in this Update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. This standard is effective for public companies for financial statements issued for annual periods beginning after December 15, 2016 (January 1, 2017 for the Company), and interim periods within those annual periods. We have adopted this accounting standard update and there was no impact to the results of operations or cash flows. In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” regarding the subsequent measurement of inventory as part of its Simplification Initiative. This standard is effective for public companies for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company), including interim periods within those fiscal years. This Update should be applied prospectively, and early application is permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of adopting this accounting standard update but do not expect this to significantly impact the results of operations, financial conditions, cash flows, or financial statement presentation. In April 2015, the FASB issued ASU No. 2015-03, “Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. To simplify the presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. In August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements—Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update), which adds the SEC staff’s guidance on the presentation of debt issuance costs associated with lines of credit to the Codification. The SEC staff stated it will not object to an entity presenting the costs of securing line-of-credit arrangements as an asset, regardless of whether there are any outstanding borrowings. The Standard is effective for financial statements issued for fiscal years beginning after December 15, 2015 (January 1, 2016 for the Company), and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted for financial statements that have not been previously issued. We have evaluated the impact of adopting this accounting standard update on our financial statements. The Company’s audited consolidated balance sheets as of December 31, 2015 and 2014 includes $349,018 and $465,251, respectively, of deferred financing cost assets (excluding $25,960 and $27,134, respectively, related to line-of-credit arrangements) that would, under the new guidance be presented as a direct reduction to liabilities. In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter of 2017 (December 31, 2016 for the Company). Early adoption is permitted. We are currently evaluating the impact of adopting this accounting standard update on our financial statement disclosures and have not concluded on an adoption method. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers," which converges the FASB's and the International Accounting Standards Board's current standards on revenue recognition. The standard provides companies with a single model to use in accounting for revenue arising from contracts with customers and supersedes current revenue guidance. The standard is effective for annual and interim periods beginning after December 15, 2017 (January 1, 2018 for the Company). Early adoption is not permitted. The standard permits companies to either apply the adoption to all periods presented, or apply the requirements in the year of adoption through a cumulative adjustment. We are currently evaluating the impact of adopting this accounting standard update on our financial statements and disclosures and have not concluded on an adoption method.

Inventory

12 Months Ended

Dec. 31, 2015

Inventory [Abstract]

Inventory

3. Inventory

Inventory consists of the following:


	December 31, 2015	December 31, 2014

Raw materials	$ 2,065,676	$ 2,746,926
Work in process	24,758	374,236
Finished goods	2,433,819	3,310,375
Reserve for obsolescence	(19,971)	(59,634)
Total inventory	$ 4,504,282	$ 6,371,903

Prepaid Expenses And Other Current Assets

12 Months Ended

Dec. 31, 2015

Prepaid Expenses And Other Current Assets [Abstract]

Prepaid Expenses And Other Current Assets

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:



	December 31, 2015	December 31, 2014

Prepaid expenses	$ 454,822	$ 679,740
Deferred financing costs	374,978	492,385
Deposits	136,583	311,562
Deferred cost of revenue	82,987	-
Total prepaid expenses and other assets	1,049,370	1,483,687
Less: Noncurrent prepaid expenses and other assets	(264,159)	(388,850)
Total prepaid expenses and other current assets	$ 785,211	$ 1,094,837

Property And Equipment

12 Months Ended

Dec. 31, 2015

Property And Equipment [Abstract]

Property And Equipment

5. Property and Equipment

Property and equipment consist of the following:


	December 31,	December 31,
	2015	2014

Equipment	$ 8,496,636	$ 8,264,804
Equipment held for lease	303,412	303,412
Leasehold improvements	2,320,368	2,328,381
	11,120,416	10,896,597
Less: Accumulated depreciation	(10,053,095)	(10,001,869)
Net property and equipment	$ 1,067,321	$ 894,728

Intangible Assets	12 Months Ended
Intangible Assets	Dec. 31, 2015
Intangible Assets [Abstract]
Intangible Assets	6. Intangible Assets As of December 31, 2015 and 2014, the Company had total intangible assets of $3,221,069 and $3,665,000. Accumulated amortization at December 31, 2015 and 2014 was $2,585,180 and $2,285,347, respectively. Amortization expense for the years 2015 and 2014 was $299,833 per year, as determined under the straight-line method. The estimated future amortization of intangible assets is $199,320 annually through July 2018, decreasing thereafter to $143,765 in 2018, $65,988 in 2019 and $27,496 through May 2020. The Company also recognized impairment charges of $443,931 during 2015 on certain 2010 intellectual property rights relating to the Company’s Odyssey Solution due to uncertainty around forecasted revenue under the Odyssey system distribution agreement beyond May, 2016. The impairment is the result of a decline in forecasted revenue attributable to this intellectual property that indicated it was probable the undiscounted future cash flows would not exceed the book value of the intellectual property. As a result, the book value of the intellectual property was reduced to its fair value as estimated using a discounted cash flow analysis. The Company evaluated the discount rate in the fair value calculation with the assistance of a third party valuation specialist (Level 3).

Accrued Liabilities

12 Months Ended

Dec. 31, 2015

Accrued Liabilities [Abstract]

Accrued Liabilities

7. Accrued Liabilities

Accrued liabilities consist of the following:


	December 31,	December 31,
	2015	2014

Accrued salaries, bonus, and benefits	$ 3,053,012	$ 2,557,557
Accrued rent	1,361,379	1,407,740
Accrued licenses and maintenance fees	666,373	661,766
Accrued interest	494,703	493,616
Accrued warranties	316,835	364,548
Accrued taxes	324,226	332,364
Other	117,465	102,479
Total accrued liabilities	6,333,993	5,920,070
Less: Long term accrued liabilities	(275,603)	(660,376)
Total current accrued liabilities	$ 6,058,390	$ 5,259,694

Certain prior year amounts have been reclassified to conform to the 2015 presentation.

Deferred Revenue

12 Months Ended

Dec. 31, 2015

Deferred Revenue [Abstract]

Deferred Revenue

8. Deferred Revenue

Deferred revenue consists of the following:


	December 31,	December 31,
	2015	2014

Product shipped, revenue deferred	$ 366,388	$ 457,348
Customer deposits	2,505,000	1,065,371
Deferred service and license fees	6,583,745	6,111,616
	9,455,133	7,634,335
Less: Long-term deferred revenue	(2,009,198)	(976,165)
Total current deferred revenue	$ 7,445,935	$ 6,658,170

Long-Term Debt And Credit Facilities

12 Months Ended

Dec. 31, 2015

Long-Term Debt And Credit Facilities [Abstract]

Long-Term Debt And Credit Facilities

9. Long-Term Debt and Credit Facilities

Debt outstanding consists of the following:


	December 31, 2015		December 31, 2014
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Healthcare Royalty Partners debt	$ 18,429,177	$ 18,429,177	$ 18,388,764	$ 18,388,764
Less current maturities	—	—	—	—
Total long term debt	$ 18,429,177	$ 18,429,177	$ 18,388,764	$ 18,388,764

Contractual principal maturities of debt at December 31, 2015 are as follows:


2016	$	-
2017		-
2018		18,429,177
2019		-
2020		-
2021 and Beyond		-
	$	18,429,177

In accordance with general accounting principles for fair value measurement, the Company’s debt and credit facilities were measured at fair value as of December 31, 2015 and December 31, 2014. Long-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value (Level 3).

The revolving line of credit and the Company’s obligations with Healthcare Royalty Partners II, L.P. (collectively, the “Credit Agreements”) are secured by substantially all of the Company’s assets. The Company is required under the Credit Agreements to maintain its primary operating account and the majority of its cash and investment balances in accounts with the primary lender.

Revolving line of credit

The Company has had a working capital line of credit with its primary lender, Silicon Valley Bank, since 2004. The revolving line of credit is secured by substantially all of the Company’s assets. The Company is also required under the revolving line of credit to maintain its primary operating account and the majority of its cash and investment balances in accounts with its primary lender. The facility was last amended on March 27, 2015 extending the maturity date three years to March 31, 2018. The current agreement requires the Company to maintain a minimum tangible net worth of not less than (no worse than) negative $22.5 million, with such minimum requirement subject to increase under certain circumstances as described in the agreement, and to maintain a liquidity ratio of greater than 1.50:1.00, excluding certain short term advances from the calculation.

As of December 31, 2015, the Company had no outstanding debt under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of December 31, 2015 the Company had a borrowing capacity of $5.2 million based on the Company’s collateralized assets.

Healthcare Royalty Partners Debt

In November 2011, the Company entered into a loan agreement with Healthcare Royalty Partners II, L.P. (formerly “Cowen Healthcare Royalty Partners II, L.P.”). Under the agreement the Company borrowed from Healthcare Royalty Partners $15 million. The Company was permitted to borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe system sales in 2012. On August 8, 2012, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the nine months ended June 30, 2012. On January 31, 2013, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the twelve months ended December 31, 2012. The loan will be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe system in cardiac ablation procedures. Under the terms of the Agreement, Healthcare Royalty Partners will be entitled to receive 100% of all royalties due to the Company under the Biosense Agreement until the loan is repaid. The loan is a full recourse loan, matures on December 31, 2018, and bears interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement are insufficient to pay all amounts of interest due on the loan, then such deficiency will increase the outstanding principal amount on the loan. After the loan obligation is repaid, the royalties under the Biosense Agreement will again be paid to the Company. The loan is also secured by certain assets and intellectual property of the Company. The Agreement also contains customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender.

Lease Obligations

12 Months Ended

Dec. 31, 2015

Lease Obligations [Abstract]

Lease Obligations

10. Lease Obligations

The Company leases its facilities under operating leases. For the years ended December 31, 2015 and 2014 rent expense was $1,205,338 and $1,068,972, respectively. The rent expense for the year ended December 31, 2015 is net of sublease income of $18,912.

In January 2006, the Company moved its primary operations into its current facilities. The facility is subject to a lease which expires in December 31, 2018. Under the terms of the lease, the Company has options to renew for up to three additional years. The lease contains an escalating rent provision which the Company has straight-lined over the term of the lease.

In the third quarter of 2013, the Company modified the existing lease agreement to terminate approximately 13,000 square feet of unimproved space. The costs associated with the termination were $515,138, and were accrued as a rent liability as of September 30, 2013. As of December 31, 2015, the remaining accrued costs associated with the termination were $284,793.

In the fourth quarter of 2015, the Company entered a sublease agreement to sublease 3,152 square feet of the first floor office space through December 31, 2018.

The future minimum lease payments under non-cancelable leases as of December 31, 2015 are as follows:



Year		Operating Lease Payments
2016	$	1,968,006
2017		1,975,514
2018		2,026,362
Total minimum lease payments		5,969,882
Less amounts representing sublease receipts		(233,248)
	$	5,736,634

Stockholders' Equity

12 Months Ended

Dec. 31, 2015

Stockholders' Equity [Abstract]

Stockholders' Equity

11. Stockholders’ Equity

The holders of common stock are entitled one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the prior rights of holders of all classes of stock having priority rights as dividends and the conditions of the Revolving Credit Agreement. No dividends have been declared or paid as of December 31, 2015.

Controlled Equity Offering

The Company entered into a Controlled Equity OfferingSM sales agreement (the “Sales Agreement”) in May 2014, as amended on March 26, 2015, with Cantor Fitzgerald & Co. (“Cantor”), as agent and/or principal, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate gross sales price of up to $18.0 million. The Company will pay Cantor a commission of 3.0% of the gross proceeds from any common stock sold through the Sales Agreement.

During the twelve months ended December 31, 2015, the Company sold an aggregate of 542,996 shares of common stock under the Sales Agreement, at an average price of approximately $1.98 per share for gross proceeds of $1,072,743 and net proceeds of $1,040,561, after deducting Cantor’s commission. As of December 31, 2015, $13.8 million of common stock remained available to be sold under this facility, subject to certain conditions as specified in the Sales Agreement.

Warrant Offering

On October 8, 2015 the Company completed an offering (the “Warrants Offering”) of transferable subscription warrants to holders of record of the Company’s common stock. Under the terms of the Warrants Offering shareholders of record on September 9, 2015 and holders of certain of the Company’s warrants (pursuant to the terms of their respective warrants) were entitled to one subscription warrant to purchase one share of common stock at a price of $1.10 per share for every four common shares held up to an aggregate of 5,755,775 shares of common stock. Pursuant to the Warrants Offering, subscription warrants to purchase 267,256 shares of common stock were exercised, resulting in gross proceeds to the Company of $293,982.

The Company has reserved shares of common stock for the exercise of warrants, the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows:


	December 31,	December 31,
	2015	2014
Warrants	2,120,365	2,197,883
Stock award plans	731,442	1,297,389
Employee Stock Purchase Plan	231,298	250,000
	3,083,105	3,745,272

Stock Award Plans

The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In August 2012, the Board of Directors adopted a stock incentive plan (the 2012 Stock Incentive Plan) which was subsequently approved by the Company’s stockholders. This plan replaces the 2002 Stock Incentive Plan which expired on March 25, 2012.

The 2012 Stock Incentive Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted shares and restricted share units to employees, directors, and consultants. Options granted under the 2012 Stock Incentive Plan expire no later than ten years from the date of grant. The exercise price of each incentive stock option shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. The vesting provisions of individual options may vary, but incentive stock options generally vest 25% on the first anniversary of each grant and 1/48 per month over the next three years. Stock appreciation rights are rights to acquire a calculated number of shares of the Company’s common stock upon exercise of the rights. The number of shares to be issued is calculated as the difference between the exercise price of the right and the aggregate market value of the underlying shares on the exercise date divided by the market value as of the exercise date. Stock appreciation rights granted under the 2012 Stock Incentive Plan generally vest 25% on the first anniversary of such grant and 1/48 per month over the next three years and expire no later than ten years from the date of grant. The Company generally issues new shares upon the exercise of stock options and stock appreciation rights.

Restricted share grants are either time-based or performance-based. Time-based restricted shares generally cliff vest three years after grant. Performance-based restricted shares vest upon the achievement of performance objectives which are determined by the Company’s Board of Directors.

Restricted stock unit grants are time-based and generally vest over a period of four years. Options granted to non-employee directors expire no later than ten years from the date of grant. The exercise price of options to non-employee directors shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. Initial grants of options to new directors generally vest over a two year period. Annual grants to directors generally vest upon the earlier of one year or the next stockholder meeting.

A summary of the option and stock appreciation rights activity for the year ended December 31, 2015 is as follows:


	Number of Options/SARs	Range of Exercise Price		Weighted Average Exercise Price per Share

Outstanding, December 31, 2014	487,146	$1.69 - $116.40		$17.21
Granted	353,350	$1.45 - $2.15		$2.07
Exercised	-	-	-
Forfeited	(134,002)	$1.45 - $91.90		$18.81
Outstanding, December 31, 2015	706,494	$1.45 - $116.40		$9.34

As of December 31, 2015, the weighted average remaining contractual life of the options and stock appreciation rights outstanding was 8.00 years. Of the 706,494 options and stock appreciation rights that were outstanding as of December 31, 2015, 235,572 were vested and exercisable with a weighted average exercise price of $22.43 per share and a weighted average remaining term of 6.42 years.

A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows:


	Year Ended December 31, 2015
							Number of		Weighted
			Weighted		Weighted		Options		Average Exercise
	Options		Average		Average		Currently		Price Per Vested
Range of Exercise Prices	Outstanding		Remaining Life		Exercise Price		Exercisable		Share
$0.00 - $10.00		607,749		8.67 years	$	3.07		136,827	$	4.07
$30.01 - $40.00		61,495		4.95 years	$	34.89		61,495	$	34.89
$40.01 - $50.00		12,250		3.44 years	$	43.90		12,250	$	43.90
$50.01 - $60.00		12,250		2.41 years	$	54.90		12,250	$	54.90
$90.01+		12,750		0.95 years	$	107.59		12,750	$	107.59
		706,494		8.00 years	$	9.34		235,572	$	22.43

The intrinsic value of options and stock appreciation rights is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options and stock appreciation rights that were in-the-money at December 31, 2015. The intrinsic value of the options and stock appreciation rights outstanding at December 31, 2015 and the intrinsic value of fully vested options and stock appreciation rights outstanding at December 31, 2015 were zero based on a closing share price of $0.74 on December 31, 2015. No options or stock appreciation rights were exercised under the Company’s stock option plans during the years ended December 31, 2014 or 2015 and the Company realized no proceeds during these periods. The weighted average grant date fair value of options and stock appreciation rights granted during the year ended December 31, 2015 was $2.07 per share.

A summary of the restricted stock unit activity for the year ended December 31, 2015 is as follows:


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2014	697,751	$3.14
Granted	391,200	$2.04
Vested	(241,775)	$3.06
Forfeited	(95,168)	$2.82
Outstanding, December 31, 2015	752,008	$2.63

The intrinsic value of restricted stock units outstanding at December 31, 2015 was $0.6 million based on a closing share price of $0.74 as of December 31, 2015. During the year ended December 31, 2015, the aggregate intrinsic value of restricted stock units vested was $0.4 million determined at the date of vesting.

During the fourth quarter of 2015, the Company made an adjustment to its forfeiture rate based on historical information, which resulted in an increase to share-based compensation of approximately $0.2 million for the year ended December 31, 2015.

As of December 31, 2015, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $2.1 million, net of estimated forfeitures of approximately $0.8 million. This cost will be amortized over a weighted average period of approximately two years on a straight-line basis over the underlying estimated service periods and will be adjusted for subsequent changes in estimated forfeitures.

2009 Employee Stock Purchase Plan

In 2009, the Company adopted its 2009 Employee Stock Purchase Plan (“ESPP”). In June 2014, our shareholders approved a proposal to amend the ESPP to increase the number of shares authorized for issuance under the ESPP by 250,000 shares. Eligible employees have the opportunity to participate in a new purchase period every 3 months. Under the terms of the plan, employees can purchase up to 15% of their compensation of the Company’s common stock, subject to an annual maximum of $25,000, at 95% of the fair market value of the stock at the end of the purchase period, subject to certain plan limitations. As of December 31, 2015, there were 231,298 remaining shares available for issuance under the Employee Stock Purchase Plan.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Fair Value Measurements

12 Months Ended

Dec. 31, 2015

Fair Value Measurements [Abstract]

Fair Value Measurements

12. Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below:

Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.

Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.

The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets at December 31, 2015:
Cash equivalents	$	524,083	524,083	—	—
Total assets at fair value	$	524,083	524,083	—	—
Liabilities at December 31, 2015:
Warrants issued May 10, 2012	$	143,681	—	—	143,681
Warrants issued August 2013	$	650,449	—	—	650,449
Total liabilities at fair value:	$	794,130	—	—	794,130
Assets at December 31, 2014:
Cash equivalents	$	5,361,053	5,361,053	—	—
Total assets at fair value	$	5,361,053	5,361,053	—	—
Liabilities at December 31, 2014:
Warrants issued May 10, 2012	$	728,712	—	—	728,712
Warrants issued August 2013	$	1,405,475	—	—	1,405,475
Total liabilities at fair value:	$	2,134,187	—	—	2,134,187

Level 1

The Company’s financial assets consist of cash equivalents invested in money market funds in the amount of $524,083 and $5,361,053 at December 31, 2015 and December 31, 2014, respectively. These assets are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during both the years ended December 31, 2015 and December 31, 2014. There were no transfers in or out of Level 1 during the year ended December 31, 2015.

Level 2

The Company does not have any financial assets or liabilities classified as Level 2.

Level 3

Due to provisions included in the warrant agreements, outstanding warrants related to the Company’s May 2012 Stock and Warrant Purchase Agreement (“PIPE warrants”) do not meet the exemptions for equity classification and as such, the Company accounts for these PIPE warrants as derivative instruments. The PIPE warrants are periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.

The remaining PIPE warrants expire in May 2018 and were valued using an option pricing model as of December 31, 2014 using the following assumptions: 1) volatility of 165.27%; 2) risk-free interest rate of 1.10%; and 3) a closing stock price of $1.48.

The PIPE warrants were revalued using an option pricing model as of December 31, 2015 using the following assumptions: 1) volatility of 113.4%; 2) risk-free interest rate of 1.06%; and 3) a closing stock price of $0.74.

Due to the provisions included in the warrant agreements, warrants outstanding in conjunction with the Company’s August 7, 2013 transaction (the “Exchange warrants”) also do not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments.

The remaining Exchange warrants expire in November 2018 and were valued using an option pricing model as of December 31, 2014 using the following assumptions: 1) volatility of 158.08%; 2) risk-free interest rate of 1.10%; and 3) a closing stock price of $1.48.

The Exchange warrants were revalued using an option pricing model as of December 31, 2015 using the following assumptions: 1) volatility of 182.94%; 2) risk-free interest rate of 1.31%; and 3) a closing stock price of $0.74.

The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility. Significant increases (decreases) in the volatility in isolation would result in a significantly higher (lower) liability fair value measurement.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the year ended December 31, 2015:


	Warrants issued May 2012	Warrants issued August 2013	Total Liabilities
Balance at beginning of period	$ 728,712	$ 1,405,475	$ 2,134,187
Issues	-	-	-
Settlements	-	-	-
Revaluation	(585,031)	(755,026)	(1,340,057)
Balance at end of period	$ 143,681	$ 650,449	$ 794,130

The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2015

Income Taxes [Abstract]

Income Taxes

13. Income Taxes

The provision for income taxes consists of the following:


	Year Ended December 31,
	2015		2014
Deferred:
Federal	$	(2,529,455)	$	(894,506)
State and local		169,266		(1,582,500)
		(2,360,189)		(2,477,006)
Valuation allowance		2,360,189		2,477,006
	$	—	$	—

The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following:


	Year Ended December 31,
	2015		2014
U.S. statutory income tax rate	34.0	%	34.0	%
State and local taxes, net of federal tax benefit	1.9	%	2.4	%
Permanent differences between book and tax	5.6	%	17.1	%
Deferred tax adjustments	(9.3)	%	(71.9)	%
State rate adjustments	(0.1)	%	(29.2)	%
Valuation allowance	(32.1)	%	47.6	%
Effective income tax rate	—	%	—	%

Included in permanent differences between book and tax in the above table are the impacts of the non-deductible mark-to-market activity associated with convertible debt and warrants as well as permanent differences such as nondeductible meals and entertainment. The deferred tax adjustment for the year ended December 31, 2014 is a write-off of a portion of the deferred tax asset related to stock compensation. The state rate adjustments are a result of changes in apportionment and various state rate law changes.

The components of the deferred tax asset are as follows:


	December 31,
	2015		2014
Current accruals	$	1,687,951	$	1,416,823
Deferred revenue		269,797		—
Depreciation and amortization		2,269,341		2,302,685
Deferred compensation		1,389,832		1,589,935
Net operating loss carryovers		32,744,557		30,246,136
Deferred tax assets		38,361,478		35,555,579
Valuation allowance		(37,912,693)		(35,555,579)
Net deferred tax assets before deferred tax liabilities		448,785		—
Accounting method changes		(448,785)		—
Net deferred tax assets	$	—	$	—

Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended, or the “Code”, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Following significant ownership changes during 2013, the Company initiated a review of the availability of its U.S. net operating loss carryforwards. As a result of this review, it was determined that approximately $290 million of the Company’s federal net operating loss carryovers would expire unused due to the limitation under IRC Section 382. The Company reduced the net operating loss carryover and corresponding valuation allowance as a result of these limitations. The remaining net operating loss carryforwards following the ownership change have been assigned a full valuation allowance against all deferred tax assets.

In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable losses, and projections for future periods over which the deferred tax assets are deductible, the Company determined that a 100% valuation allowance of deferred tax assets was appropriate. The valuation allowance for deferred tax assets includes amounts for which subsequently recognized tax benefits will be applied directly to the contributed capital.

As of December 31, 2015, we had gross federal net operating loss carryforwards of approximately $92.7 million. The federal net operating loss carryforwards will expire between 2017 and 2035. As of December 31, 2015, we had state net operating loss deferred tax assets of approximately $1.2 million which will expire at various dates between 2016 and 2035 if not utilized.

The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. As the Company has a federal net operating loss carryforward from the year ended December 31, 1997 forward, all tax years from 1997 forward are subject to examination. As states have varying carryforward periods, and the Company has recently entered into additional states, the states are generally subject to examination for the previous 10 years or less.

The Company recognizes interest accrued, if any, net of tax and penalties, related to unrecognized tax benefits as components of income tax provision as applicable. As of December 31, 2015 accrued interest and penalties were less than $0.1 million.

At December 31, 2015 and 2014, the Company had approximately $0.3 million and $0.2 million, respectively, in reserves for uncertain tax positions.

Net Loss Per Share

12 Months Ended

Dec. 31, 2015

Net Loss Per Share [Abstract]

Net Loss Per Share

14. Net Loss per Share

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations:


	2015		2014
Numerator:
Numerator for basic EPS	$	(7,352,775)	$	(5,202,441)
Numerator for diluted EPS	$	(7,352,775)	$	(5,202,441)
Denominator:
Denominator for basic EPS—weighted average shares		21,113,203		19,945,038
Denominator for diluted EPS		21,113,203		19,945,038
Basic EPS	$	(0.35)	$	(0.26)
Diluted EPS	$	(0.35)	$	(0.26)

The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows:


	December 31,
	2015	2014
Shares issuable upon vesting/exercise of:
Options to purchase common stock	706,494	487,146
Restricted stock units	752,008	697,751
Warrants	2,120,365	2,197,883
	3,578,867	3,382,780

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2015
Empoyee Benefit Plan [Abstract]
Employee Benefit Plan	15. Employee Benefit Plan The Company offers employees the opportunity to participate in a 401(k) plan. Employer contributions are discretionary under the 401(k) plan. Currently the Company does not match employee contributions.

Product Warranty Provisions

12 Months Ended

Dec. 31, 2015

Product Warranty Provisions [Abstract]

Product Warranty Provisions

16. Product Warranty Provisions

The Company’s standard policy is to warrant all Niobe, Odyssey and Vdrive systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.

Accrued warranty, which is included in other accrued liabilities, consists of the following:


	December 31, 2015		December 31, 2014
Warranty accrual, beginning of the fiscal period	$	364,548	$	501,212
Accrual adjustment for product warranty		171,384		84,402
Payments made		(219,097)		(221,066)
Warranty accrual, end of the fiscal period	$	316,835	$	364,548

Commitments And Contingencies	12 Months Ended
Commitments And Contingencies	Dec. 31, 2015
Commitments And Contingencies [Abstract]
Commitments And Contingencies	17. Commitments and Contingencies The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.

Segment Information

12 Months Ended

Dec. 31, 2015

Segment Information [Abstract]

Segment Information

18. Segment Information

The Company considers reporting segments in accordance with general accounting principles for disclosures about segments of an enterprise and related information. The Company’s system and disposable devices are developed and marketed to a broad base of hospitals in the United States and internationally. The Company considers all such sales to be part of a single operating segment. Geographic revenues for the years ended December 31, 2015 and 2014 were as follows:


	Year Ended December 31,
	2015		2014
United States	$	19,757,986	$	21,626,788
International		17,916,538		13,384,488
Total	$	37,674,524	$	35,011,276

All of the Company’s long-lived assets are located in the United States. Revenues are attributed to countries based on the location of the customer.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	19. Subsequent Events None.

Valuation And Qualifying Accounts

12 Months Ended

Dec. 31, 2015

Valuation And Qualifying Accounts [Abstract]

Valuation And Qualifying Accounts

SCHEDULE II

VALUATION AND QUALIFYING ACCOUNTS

FOR THE YEARS ENDED DECEMBER 31, 2015 AND 2014


			Additions
	Balance at		Charged to
	Beginning of		Cost and				Balance at the
	Year		Expenses		Deductions		End of Year
Allowance for doubtful accounts and returns:
Year ended December 31, 2015	$	131,464	$	(9,463)	$	(28,523)	$	93,478
Year ended December 31, 2014	$	383,077	$	48,742	$	(300,355)	$	131,464

Allowance for inventories valuation:
Year ended December 31, 2015	$	59,634	$	42,258	$	(81,921)	$	19,971
Year ended December 31, 2014	$	80,213	$	6,970	$	(27,549)	$	59,634

Summary Of Significant Accounting Policies (Policies)	12 Months Ended
Summary Of Significant Accounting Policies (Policies)	Dec. 31, 2015
Summary Of Significant Accounting Policies [Abstract]
Cash And Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No cash was restricted at December 31, 2015 or 2014.
Accounts Receivable And Allowance For Uncollectible Accounts	Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators.
Financial Instruments	Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 12 for disclosure of fair value measurements.
Inventory	Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items.
Property And Equipment	Property and Equipment Property and equipment consist primarily of leasehold improvements, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years.
Long-Lived Assets	Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs.
Intangible Assets	Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs.
Use Of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates.
Revenue And Costs Of Revenue	Revenue and Costs of Revenue The Company adopted Accounting Standards Update 2009-13, Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”) in the fourth quarter of 2009, effective as of January 1, 2009. ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Research And Development Costs	Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic alliances under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2015 or 2014 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned.
Share-Based Compensation	Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date. The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares and units granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments. Shares purchased by employees under the 2009 Employee Stock Purchase Plan are considered to be non-compensatory.
Net Earnings (Loss) Per Common Share	Net Earnings (Loss) per Common Share Basic earnings (loss) per common share are computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed by dividing the earnings (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. In addition, the application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable because the Company’s unearned restricted shares do not contractually participate in its losses. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2015, the Company had 706,494 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $9.34 per share and 2,120,365 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $4.82 per share. The Company had no unearned restricted shares outstanding for the period ended December 31, 2015.
Income Taxes	Income Taxes In accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized.
Product Warranty Provisions	Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate.
Patent Costs	Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
Concentrations Of Risk	Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. Biosense Webster Inc. accounted for $3,514,897 and $4,651,490, or 9%, and 13%, of total net revenue for the years ended December 31, 2015, and 2014, respectively. No other single customer accounted for more than 10% of total revenue for the year ended December 31, 2015.
Reclassifications	Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 - Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update. In November 2015, the FASB issued Accounting Standards Update (“ASU” or “Update”) No. 2015-17, “Income Taxes (Topic 740): To simplify the presentation of deferred income taxes”. The amendments in this Update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. This standard is effective for public companies for financial statements issued for annual periods beginning after December 15, 2016 (January 1, 2017 for the Company), and interim periods within those annual periods. We have adopted this accounting standard update and there was no impact to the results of operations or cash flows. In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” regarding the subsequent measurement of inventory as part of its Simplification Initiative. This standard is effective for public companies for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company), including interim periods within those fiscal years. This Update should be applied prospectively, and early application is permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of adopting this accounting standard update but do not expect this to significantly impact the results of operations, financial conditions, cash flows, or financial statement presentation. In April 2015, the FASB issued ASU No. 2015-03, “Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. To simplify the presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. In August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements—Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update), which adds the SEC staff’s guidance on the presentation of debt issuance costs associated with lines of credit to the Codification. The SEC staff stated it will not object to an entity presenting the costs of securing line-of-credit arrangements as an asset, regardless of whether there are any outstanding borrowings. The Standard is effective for financial statements issued for fiscal years beginning after December 15, 2015 (January 1, 2016 for the Company), and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted for financial statements that have not been previously issued. We have evaluated the impact of adopting this accounting standard update on our financial statements. The Company’s audited consolidated balance sheets as of December 31, 2015 and 2014 includes $349,018 and $465,251, respectively, of deferred financing cost assets (excluding $25,960 and $27,134, respectively, related to line-of-credit arrangements) that would, under the new guidance be presented as a direct reduction to liabilities. In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter of 2017 (December 31, 2016 for the Company). Early adoption is permitted. We are currently evaluating the impact of adopting this accounting standard update on our financial statement disclosures and have not concluded on an adoption method. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers," which converges the FASB's and the International Accounting Standards Board's current standards on revenue recognition. The standard provides companies with a single model to use in accounting for revenue arising from contracts with customers and supersedes current revenue guidance. The standard is effective for annual and interim periods beginning after December 15, 2017 (January 1, 2018 for the Company). Early adoption is not permitted. The standard permits companies to either apply the adoption to all periods presented, or apply the requirements in the year of adoption through a cumulative adjustment. We are currently evaluating the impact of adopting this accounting standard update on our financial statements and disclosures and have not concluded on an adoption method.

Inventory (Tables)

12 Months Ended

Dec. 31, 2015

Inventory [Abstract]

Schedule Of Inventory


	December 31, 2015	December 31, 2014

Raw materials	$ 2,065,676	$ 2,746,926
Work in process	24,758	374,236
Finished goods	2,433,819	3,310,375
Reserve for obsolescence	(19,971)	(59,634)
Total inventory	$ 4,504,282	$ 6,371,903

Prepaid Expenses And Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2015

Prepaid Expenses And Other Current Assets [Abstract]

Schedule Of Prepaid Expenses And Other Current Assets



	December 31, 2015	December 31, 2014

Prepaid expenses	$ 454,822	$ 679,740
Deferred financing costs	374,978	492,385
Deposits	136,583	311,562
Deferred cost of revenue	82,987	-
Total prepaid expenses and other assets	1,049,370	1,483,687
Less: Noncurrent prepaid expenses and other assets	(264,159)	(388,850)
Total prepaid expenses and other current assets	$ 785,211	$ 1,094,837

Property And Equipment (Tables)

12 Months Ended

Dec. 31, 2015

Property And Equipment [Abstract]

Schedule Of Property And Equipment


	December 31,	December 31,
	2015	2014

Equipment	$ 8,496,636	$ 8,264,804
Equipment held for lease	303,412	303,412
Leasehold improvements	2,320,368	2,328,381
	11,120,416	10,896,597
Less: Accumulated depreciation	(10,053,095)	(10,001,869)
Net property and equipment	$ 1,067,321	$ 894,728

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2015

Accrued Liabilities [Abstract]

Schedule Of Accrued Liabilities


	December 31,	December 31,
	2015	2014

Accrued salaries, bonus, and benefits	$ 3,053,012	$ 2,557,557
Accrued rent	1,361,379	1,407,740
Accrued licenses and maintenance fees	666,373	661,766
Accrued interest	494,703	493,616
Accrued warranties	316,835	364,548
Accrued taxes	324,226	332,364
Other	117,465	102,479
Total accrued liabilities	6,333,993	5,920,070
Less: Long term accrued liabilities	(275,603)	(660,376)
Total current accrued liabilities	$ 6,058,390	$ 5,259,694

Deferred Revenue (Tables)

12 Months Ended

Dec. 31, 2015

Deferred Revenue [Abstract]

Schedule Of Deferred Revenue


	December 31,	December 31,
	2015	2014

Product shipped, revenue deferred	$ 366,388	$ 457,348
Customer deposits	2,505,000	1,065,371
Deferred service and license fees	6,583,745	6,111,616
	9,455,133	7,634,335
Less: Long-term deferred revenue	(2,009,198)	(976,165)
Total current deferred revenue	$ 7,445,935	$ 6,658,170

Long-Term Debt And Credit Facilities (Tables)

12 Months Ended

Dec. 31, 2015

Long-Term Debt And Credit Facilities [Abstract]

Schedule Of Debt Outstanding


	December 31, 2015		December 31, 2014
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Healthcare Royalty Partners debt	$ 18,429,177	$ 18,429,177	$ 18,388,764	$ 18,388,764
Less current maturities	—	—	—	—
Total long term debt	$ 18,429,177	$ 18,429,177	$ 18,388,764	$ 18,388,764

Schedule Of Contractual Principal Maturities Of Debt


2016	$	-
2017		-
2018		18,429,177
2019		-
2020		-
2021 and Beyond		-
	$	18,429,177

Lease Obligations (Tables)

12 Months Ended

Dec. 31, 2015

Lease Obligations [Abstract]

Schedule Of Future Minimum Lease Payments



Year		Operating Lease Payments
2016	$	1,968,006
2017		1,975,514
2018		2,026,362
Total minimum lease payments		5,969,882
Less amounts representing sublease receipts		(233,248)
	$	5,736,634

Stockholder's Equity (Tables)

12 Months Ended

Dec. 31, 2015

Stockholders' Equity [Abstract]

Summary Of Reserved Shares Of Common Stock


	December 31,	December 31,
	2015	2014
Warrants	2,120,365	2,197,883
Stock award plans	731,442	1,297,389
Employee Stock Purchase Plan	231,298	250,000
	3,083,105	3,745,272

Summary Of Option And Stock Appreciation Rights Activity


	Number of Options/SARs	Range of Exercise Price		Weighted Average Exercise Price per Share

Outstanding, December 31, 2014	487,146	$1.69 - $116.40		$17.21
Granted	353,350	$1.45 - $2.15		$2.07
Exercised	-	-	-
Forfeited	(134,002)	$1.45 - $91.90		$18.81
Outstanding, December 31, 2015	706,494	$1.45 - $116.40		$9.34

Summary Of Options And Stock Appreciation Rights Outstanding By Range Of Exercise Price


	Year Ended December 31, 2015
							Number of		Weighted
			Weighted		Weighted		Options		Average Exercise
	Options		Average		Average		Currently		Price Per Vested
Range of Exercise Prices	Outstanding		Remaining Life		Exercise Price		Exercisable		Share
$0.00 - $10.00		607,749		8.67 years	$	3.07		136,827	$	4.07
$30.01 - $40.00		61,495		4.95 years	$	34.89		61,495	$	34.89
$40.01 - $50.00		12,250		3.44 years	$	43.90		12,250	$	43.90
$50.01 - $60.00		12,250		2.41 years	$	54.90		12,250	$	54.90
$90.01+		12,750		0.95 years	$	107.59		12,750	$	107.59
		706,494		8.00 years	$	9.34		235,572	$	22.43

Summary Of Restricted Stock Unit Activity


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2014	697,751	$3.14
Granted	391,200	$2.04
Vested	(241,775)	$3.06
Forfeited	(95,168)	$2.82
Outstanding, December 31, 2015	752,008	$2.63

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2015

Fair Value Measurements [Abstract]

Assets And Liabilities Measured At Fair Value On Recurring Basis By Level


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets at December 31, 2015:
Cash equivalents	$	524,083	524,083	—	—
Total assets at fair value	$	524,083	524,083	—	—
Liabilities at December 31, 2015:
Warrants issued May 10, 2012	$	143,681	—	—	143,681
Warrants issued August 2013	$	650,449	—	—	650,449
Total liabilities at fair value:	$	794,130	—	—	794,130
Assets at December 31, 2014:
Cash equivalents	$	5,361,053	5,361,053	—	—
Total assets at fair value	$	5,361,053	5,361,053	—	—
Liabilities at December 31, 2014:
Warrants issued May 10, 2012	$	728,712	—	—	728,712
Warrants issued August 2013	$	1,405,475	—	—	1,405,475
Total liabilities at fair value:	$	2,134,187	—	—	2,134,187

Summary Of Changes In Fair Value Of Level 3 Financial Liabilities


	Warrants issued May 2012	Warrants issued August 2013	Total Liabilities
Balance at beginning of period	$ 728,712	$ 1,405,475	$ 2,134,187
Issues	-	-	-
Settlements	-	-	-
Revaluation	(585,031)	(755,026)	(1,340,057)
Balance at end of period	$ 143,681	$ 650,449	$ 794,130

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2015

Income Taxes [Abstract]

Schedule Of Provision For Income Taxes


	Year Ended December 31,
	2015		2014
Deferred:
Federal	$	(2,529,455)	$	(894,506)
State and local		169,266		(1,582,500)
		(2,360,189)		(2,477,006)
Valuation allowance		2,360,189		2,477,006
	$	—	$	—

Schedule Of Reconciliation Of Federal Income Tax Rate


	Year Ended December 31,
	2015		2014
U.S. statutory income tax rate	34.0	%	34.0	%
State and local taxes, net of federal tax benefit	1.9	%	2.4	%
Permanent differences between book and tax	5.6	%	17.1	%
Deferred tax adjustments	(9.3)	%	(71.9)	%
State rate adjustments	(0.1)	%	(29.2)	%
Valuation allowance	(32.1)	%	47.6	%
Effective income tax rate	—	%	—	%

Schedule Of Components Of Deferred Tax Asset


	December 31,
	2015		2014
Current accruals	$	1,687,951	$	1,416,823
Deferred revenue		269,797		—
Depreciation and amortization		2,269,341		2,302,685
Deferred compensation		1,389,832		1,589,935
Net operating loss carryovers		32,744,557		30,246,136
Deferred tax assets		38,361,478		35,555,579
Valuation allowance		(37,912,693)		(35,555,579)
Net deferred tax assets before deferred tax liabilities		448,785		—
Accounting method changes		(448,785)		—
Net deferred tax assets	$	—	$	—

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2015

Net Loss Per Share [Abstract]

Schedule Of Computation Of Basic And Diluted Earnings Per Share


	2015		2014
Numerator:
Numerator for basic EPS	$	(7,352,775)	$	(5,202,441)
Numerator for diluted EPS	$	(7,352,775)	$	(5,202,441)
Denominator:
Denominator for basic EPS—weighted average shares		21,113,203		19,945,038
Denominator for diluted EPS		21,113,203		19,945,038
Basic EPS	$	(0.35)	$	(0.26)
Diluted EPS	$	(0.35)	$	(0.26)

Schedule Of Anti-Dilutive Securities Excluded From Computation Of Diluted Earnings Per Share


	December 31,
	2015	2014
Shares issuable upon vesting/exercise of:
Options to purchase common stock	706,494	487,146
Restricted stock units	752,008	697,751
Warrants	2,120,365	2,197,883
	3,578,867	3,382,780

Product Warranty Provisions (Tables)

12 Months Ended

Dec. 31, 2015

Product Warranty Provisions [Abstract]

Schedule Of Accrued Warranty


	December 31, 2015		December 31, 2014
Warranty accrual, beginning of the fiscal period	$	364,548	$	501,212
Accrual adjustment for product warranty		171,384		84,402
Payments made		(219,097)		(221,066)
Warranty accrual, end of the fiscal period	$	316,835	$	364,548

Segment Information (Tables)

12 Months Ended

Dec. 31, 2015

Segment Information [Abstract]

Schedule Of Geographic Revenues


	Year Ended December 31,
	2015		2014
United States	$	19,757,986	$	21,626,788
International		17,916,538		13,384,488
Total	$	37,674,524	$	35,011,276

Description Of Business (Details)	12 Months Ended
Description Of Business (Details)	Dec. 31, 2015 USD ($) item	Dec. 31, 2014 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Cumulative net losses \| $	$ (465,958,678)	$ (458,605,903)
Installed base \| item	125
Minimum [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Annual plan percentage to rebalance and reduce operating expenses	15.00%
Maximum [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Annual plan percentage to rebalance and reduce operating expenses	20.00%
Revolving Credit Facility [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Line of credit maturity date	Mar. 31, 2018

Summary Of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Line Items]
Restricted cash	$ 0	$ 0
Deferred revenue, amortization period	1 year
Research and development receivables	$ 0	$ 0
Options and stock appreciation rights outstanding	706,494	487,146
Weighted average exercise price	$ 9.34	$ 17.21
Common stock issuable upon exercise of outstanding warrants	2,120,365	2,197,883
Exercise price of warrants	$ 4.82
Standard product warranty, coverage term	1 year
Revenues	$ 37,674,524	$ 35,011,276
Deferred financing cost assets	$ 374,978	492,385
Minimum [Member]
Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Intangible assets, estimated useful lives	10 years
Share-based compensation, requisite service period	1 year
Maximum [Member]
Accounting Policies [Line Items]
Property and equipment, estimated useful lives	10 years
Intangible assets, estimated useful lives	15 years
Share-based compensation, requisite service period	4 years
Net Revenue [Member] \| Customer Concentration Risk [Member] \| Maximum [Member]
Accounting Policies [Line Items]
Revenues percentage	10.00%
Long-Term Debt [Member]
Accounting Policies [Line Items]
Deferred financing cost assets	$ 349,018	465,251
Line-Of-Credit Arrangements [Member]
Accounting Policies [Line Items]
Deferred financing cost assets	$ 25,960	27,134
Restricted Stock [Member]
Accounting Policies [Line Items]
Unvested restricted shares	0
Biosense Webster Inc [Member] \| Net Revenue [Member]
Accounting Policies [Line Items]
Revenues	$ 3,514,897	$ 4,651,490
Revenues percentage	9.00%	13.00%

Inventory (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Inventory [Abstract]
Raw materials	$ 2,065,676	$ 2,746,926
Work in process	24,758	374,236
Finished goods	2,433,819	3,310,375
Reserve for obsolescence	(19,971)	(59,634)
Total inventory	$ 4,504,282	$ 6,371,903

Prepaid Expenses And Other Current Assets (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid expenses	$ 454,822	$ 679,740
Deferred financing costs	374,978	492,385
Deposits	136,583	311,562
Deferred cost of revenue	82,987
Total prepaid expenses and other assets	1,049,370	1,483,687
Less: Noncurrent prepaid expenses and other assets	(264,159)	(388,850)
Total prepaid expenses and other current assets	$ 785,211	$ 1,094,837

Property And Equipment (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 11,120,416	$ 10,896,597
Less: Accumulated depreciation	(10,053,095)	(10,001,869)
Net property and equipment	1,067,321	894,728
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	8,496,636	8,264,804
Equipment Held For Lease [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	303,412	303,412
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 2,320,368	$ 2,328,381

Intangible Assets (Details) - USD ($)	12 Months Ended
Intangible Assets (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Intangible Assets [Abstract]
Total intangible assets	$ 3,221,069	$ 3,665,000
Accumulated amortization	2,585,180	2,285,347
Amortization expense	299,833	$ 299,833
Future amortization expense through 2017	199,320
Future amortization expense in 2018	143,765
Future amortization expense in 2019	65,988
Future amortization expense in 2020	27,496
Impairment charges	$ 443,931

Accrued Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities [Abstract]
Accrued salaries, bonus, and benefits	$ 3,053,012	$ 2,557,557
Accrued rent	1,361,379	1,407,740
Accrued licenses and maintenance fees	666,373	661,766
Accrued interest	494,703	493,616
Accrued warranties	316,835	364,548	$ 501,212
Accrued taxes	324,226	332,364
Other	117,465	102,479
Total accrued liabilities	6,333,993	5,920,070
Less: Long term accrued liabilities	(275,603)	(660,376)
Total current accrued liabilities	$ 6,058,390	$ 5,259,694

Deferred Revenue (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 9,455,133	$ 7,634,335
Less: Long-term deferred revenue	(2,009,198)	(976,165)
Total current deferred revenue	7,445,935	6,658,170
Product Shipped, Revenue Deferred [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	366,388	457,348
Customer Deposits [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	2,505,000	1,065,371
Deferred Service And License Fees [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 6,583,745	$ 6,111,616

Long-Term Debt And Credit Facilities (Revolving Line Of Credit) (Narrative) (Details) - Revolving Credit Facility [Member]	12 Months Ended
	Dec. 31, 2015 USD ($)
Line of Credit Facility [Line Items]
Line of credit maturity date	Mar. 31, 2018
Minimum tangible net worth requirement	$ (22,500,000)
Line of credit facility, amount outstanding	0
Line of credit facility, current borrowing capacity	$ 5,200,000
Minimum [Member]
Line of Credit Facility [Line Items]
Liquidity ratio	1.50

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Long-Term Debt And Credit Facilities (Healthcare Royalty Partners Debt) (Narrative) (Details) - Healthcare Royalty Partners Debt [Member] - USD ($) $ in Millions			1 Months Ended	12 Months Ended
	Jan. 31, 2013	Aug. 08, 2012	Nov. 30, 2011	Dec. 31, 2015
Debt Instrument [Line Items]
Amount borrowed	$ 2.5	$ 2.5	$ 15.0
Additional amount which may be borrowed			$ 5.0
Percentage of royalties entitled to receive			100.00%
Maturity date				Dec. 31, 2018
Annual interest rate			16.00%

Long-Term Debt And Credit Facilities (Schedule Of Debt Outstanding) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Total debt	$ 18,429,177
Total long term debt	18,429,177	$ 18,388,764
Carrying Amount [Member]
Debt Instrument [Line Items]
Less current maturities
Total long term debt	18,429,177	18,388,764
Estimated Fair Value [Member]
Debt Instrument [Line Items]
Less current maturities
Total long term debt	18,429,177	18,388,764
Healthcare Royalty Partners Debt [Member] \| Carrying Amount [Member]
Debt Instrument [Line Items]
Total debt	18,429,177	18,388,764
Healthcare Royalty Partners Debt [Member] \| Estimated Fair Value [Member]
Debt Instrument [Line Items]
Total debt	$ 18,429,177	$ 18,388,764

Long-Term Debt And Credit Facilities (Contractual Principal Maturities Of Debt) (Details)	Dec. 31, 2015 USD ($)
Long-Term Debt And Credit Facilities [Abstract]
2016
2017
2018	18,429,177
2019
2020
2021 and Beyond
Total debt	$ 18,429,177

Lease Obligations (Narrative) (Details)	3 Months Ended		12 Months Ended
Lease Obligations (Narrative) (Details)	Dec. 31, 2015 USD ($) ft²	Sep. 30, 2013 USD ($) ft²	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Lease Obligations [Abstract]
Rent expense			$ 1,205,338	$ 1,068,972
Sublease income			$ 18,912
Lease renewal term			3 years
Area of terminated leased space \| ft²		13,000
Accrued costs of rent liability	$ 284,793	$ 515,138	$ 284,793
Area of subleased space \| ft²	3,152

Lease Obligations (Schedule of Future Minimum Lease Payments) (Details)	Dec. 31, 2015 USD ($)
Lease Obligations [Abstract]
2016	$ 1,968,006
2017	1,975,514
2018	2,026,362
Total minimum lease payments	5,969,882
Less amounts representing sublease receipts	(233,248)
Net minimum lease payments	$ 5,736,634

Stockholders' Equity (Narrative) (Details)	1 Months Ended		12 Months Ended
Stockholders' Equity (Narrative) (Details)	Jun. 30, 2014 shares	May 31, 2014 USD ($)	Dec. 31, 2015 USD ($) $ / shares item shares	Dec. 31, 2014 USD ($) shares	Dec. 31, 2009 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Votes per share \| item			1
Dividends declared			$ 0
Dividends paid			$ 0
Share price \| $ / shares			$ 0.74
Gross proceeds from common stock sold			$ 941,354	$ 2,853,673
Exercise price of warrants \| $ / shares			$ 4.82
Warrants outstanding \| shares			2,120,365	2,197,883
Weighted average remaining contractual life			8 years
Options and stock appreciation rights outstanding \| shares			706,494	487,146
Options and stock appreciation rights vested and exercisable \| shares			235,572
Options and stock appreciation rights weighted average exercise price \| $ / shares			$ 22.43
Options and stock appreciation rights weighted average remaining term			6 years 5 months 1 day
Options and stock appreciation rights intrinsic value			$ 0
Options and stock appreciation rights exercised \| shares				0
Proceeds from options and stock appreciation rights exercised			$ 0	$ 0
Weighted average grant date fair value of options and stock appreciation rights granted \| $ / shares			$ 2.07
Adjustment for forfeiture rate			$ (200,000)
Total compensation cost not yet recognized			2,100,000
Estimated forfeitures			$ 800,000
Weighted average amortization period of total compensation cost not yet recognized			2 years
2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration term			10 years
Exercise price as percentage of fair value			100.00%
2009 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares authorized for issuance under the Plan \| shares	250,000
Eligible employees new purchase period			3 months
Percentage of compensation eligible employees can use to purchase common stock, maximum					15.00%
Compensation amount eligible employees can use to purchase common stock, maximum					$ 25,000
Percentage of fair value eligible employees can purchase common stock					95.00%
Shares available under ESPP \| shares			231,298
September 9, 2015 Warrants Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Offering commencement date			Sep. 09, 2015
Number of common shares exercised upon conversion of warrants \| shares			267,256
Exercise price of warrants \| $ / shares			$ 1.10
Warrants outstanding \| shares			5,755,775
Number of common shares to purchase per subscription warrant \| shares			0.25
Gross proceeds from stock warrants exercised			$ 293,982
Sales Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross sales price		$ 18,000,000
Commission percentage of gross proceeds		3.00%
Aggregate shares of common stock sold \| shares			542,996
Share price \| $ / shares			$ 1.98
Gross proceeds from common stock sold			$ 1,072,743
Net proceeds from common stock sold			1,040,561
Remaining common stock available			$ 13,800,000
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration term			10 years
Exercise price as percentage of fair value			100.00%
Director [Member] \| Initial Grant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period			2 years
Director [Member] \| Annual Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period			1 year
Incentive Stock Options [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period			3 years
Incentive Stock Options [Member] \| First Anniversary [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting percentage			25.00%
Incentive Stock Options [Member] \| Subsequent Monthly Vesting [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting percentage			2.0833%
Stock Option, Appreciation Rights And Warrants [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration term			10 years
Options vesting period			3 years
Stock Option, Appreciation Rights And Warrants [Member] \| First Anniversary [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting percentage			25.00%
Stock Option, Appreciation Rights And Warrants [Member] \| Subsequent Monthly Vesting [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting percentage			2.0833%
Time Based Restricted Shares [Member] \| 2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period			3 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares outstanding \| shares			0
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price \| $ / shares			$ 0.74
Options vesting period			4 years
Restricted shares granted \| shares			391,200
Restricted shares outstanding \| shares			752,008	697,751
Intrinsic value of restricted awards outstanding			$ 600,000
Intrinsic value of restricted awards vested			$ 400,000

Stockholders' Equity (Summary Of Reserved Shares Of Common Stock) (Details) - shares	Dec. 31, 2015	Dec. 31, 2014
Stockholders' Equity [Abstract]
Warrants	2,120,365	2,197,883
Stock award plans	731,442	1,297,389
Employee Stock Purchase Plan	231,298	250,000
Total Reserved Shares of Common Stock	3,083,105	3,745,272

Stockholders' Equity (Summary Of Option And Stock Appreciation Rights Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, December 31, 2014	487,146
Number of Options/SARs, Granted	353,350
Number of Options/SARs, Exercised		0
Number of Options/SARs, Forfeited	(134,002)
Number of Options/SARs, Outstanding, December 31, 2015	706,494	487,146
Weighted Average Exercise Price per Share, Outstanding, December 31, 2014	$ 17.21
Weighted Average Exercise Price per Share, Granted	2.07
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Forfeited	18.81
Weighted Average Exercise Price per Share, Outstanding, December 31, 2015	9.34	$ 17.21
$1.69 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit		1.69
Range of Exercise Prices, Upper Limit		$ 116.40
$1.45 - $2.15 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit	1.45
Range of Exercise Prices, Upper Limit	2.15
$1.45 - $91.90 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit	1.45
Range of Exercise Prices, Upper Limit	91.90
$1.45 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit	1.45
Range of Exercise Prices, Upper Limit	$ 116.40

Stockholders' Equity (Summary Of Options And Stock Appreciation Rights Outstanding By Range Of Exercise Price) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding	706,494	487,146
Weighted Average Remaining Life	8 years
Weighted Average Exercise Price	$ 9.34	$ 17.21
Number of Options Currently Exercisable	235,572
Weighted Average Exercise Price per Vested Share	$ 22.43
$0.00 - $10.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	0.00
Range of Exercise Prices, Upper Limit	$ 10.00
Options Outstanding	607,749
Weighted Average Remaining Life	8 years 8 months 1 day
Weighted Average Exercise Price	$ 3.07
Number of Options Currently Exercisable	136,827
Weighted Average Exercise Price per Vested Share	$ 4.07
$30.01 - $40.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	30.01
Range of Exercise Prices, Upper Limit	$ 40.00
Options Outstanding	61,495
Weighted Average Remaining Life	4 years 11 months 12 days
Weighted Average Exercise Price	$ 34.89
Number of Options Currently Exercisable	61,495
Weighted Average Exercise Price per Vested Share	$ 34.89
$40.01 - $50.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	40.01
Range of Exercise Prices, Upper Limit	$ 50.00
Options Outstanding	12,250
Weighted Average Remaining Life	3 years 5 months 9 days
Weighted Average Exercise Price	$ 43.90
Number of Options Currently Exercisable	12,250
Weighted Average Exercise Price per Vested Share	$ 43.90
$50.01 - $60.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	50.01
Range of Exercise Prices, Upper Limit	$ 60.00
Options Outstanding	12,250
Weighted Average Remaining Life	2 years 4 months 28 days
Weighted Average Exercise Price	$ 54.90
Number of Options Currently Exercisable	12,250
Weighted Average Exercise Price per Vested Share	$ 54.90
$90.01+ [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	$ 90.01
Options Outstanding	12,750
Weighted Average Remaining Life	11 months 12 days
Weighted Average Exercise Price	$ 107.59
Number of Options Currently Exercisable	12,750
Weighted Average Exercise Price per Vested Share	$ 107.59

Stockholders' Equity (Summary Of Restricted Stock Unit Activity) (Details) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2015 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Awards, Outstanding, December 31, 2014 \| shares	697,751
Number of Restricted Awards, Granted \| shares	391,200
Number of Restricted Awards, Vested \| shares	(241,775)
Number of Restricted Awards, Forfeited \| shares	(95,168)
Number of Restricted Awards, Outstanding, December 31, 2015 \| shares	752,008
Weighted Average Grant Date Fair Value per Award, Outstanding, December 31, 2014 \| $ / shares	$ 3.14
Weighted Average Grant Date Fair Value per Award, Granted \| $ / shares	2.04
Weighted Average Grant Date Fair Value per Unit, Vested \| $ / shares	3.06
Weighted Average Grant Date Fair Value per Award, Forfeited \| $ / shares	2.82
Weighted Average Grant Date Fair Value per Award, Outstanding, December 31, 2015 \| $ / shares	$ 2.63

Fair Value Measurements (Narrative) (Details) - USD ($)	12 Months Ended
Fair Value Measurements (Narrative) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Cash equivalents invested in money market funds	$ 524,083	$ 5,361,053
Closing stock price	$ 0.74
PIPE Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant expiration date	May 01, 2018
Volatility rate	113.40%	165.27%
Risk-free interest rate	1.06%	1.10%
Closing stock price	$ 0.74	$ 1.48
Exchange Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant expiration date	Nov. 01, 2018
Volatility rate	182.94%	158.08%
Risk-free interest rate	1.31%	1.10%
Closing stock price	$ 0.74	$ 1.48
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Cash equivalents invested in money market funds	$ 524,083	$ 5,361,053

Fair Value Measurements (Assets And Liabilities Measured At Fair Value On Recurring Basis By Level) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 524,083	$ 5,361,053
Total assets at fair value	524,083	5,361,053
Warrants issued	794,130	2,134,187
Total liabilities at fair value	794,130	2,134,187
Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	143,681	728,712
Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	650,449	1,405,475
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	524,083	5,361,053
Total assets at fair value	524,083	5,361,053
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total assets at fair value
Total liabilities at fair value
Significant Other Observable Inputs (Level 2) [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] \| Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	794,130	2,134,187
Significant Unobservable Inputs (Level 3) [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	143,681	728,712
Significant Unobservable Inputs (Level 3) [Member] \| Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	$ 650,449	$ 1,405,475

Fair Value Measurements (Summary Of Changes In Fair Value Of Level 3 Financial Liabilities) (Details)	12 Months Ended
	Dec. 31, 2015 USD ($)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Liabilities, Balance at beginning of period	$ 2,134,187
Liabilities, Issues
Liabilities, Settlements
Liabilities, Revaluation	(1,340,057)
Liabilities, Balance at end of period	794,130
Warrants Issued May 10, 2012 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Liabilities, Balance at beginning of period	728,712
Liabilities, Issues
Liabilities, Settlements
Liabilities, Revaluation	(585,031)
Liabilities, Balance at end of period	143,681
Warrants Issued August 2013 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Liabilities, Balance at beginning of period	1,405,475
Liabilities, Issues
Liabilities, Settlements
Liabilities, Revaluation	(755,026)
Liabilities, Balance at end of period	$ 650,449

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Valid portion of valuation allowance percentage	100.00%
Number of prior years subject to examination	10 years
Accrued interest and penalties	$ 100,000
Reserves for uncertain tax positions	$ 300,000	$ 200,000
Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Tax year subject to examination	1997
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryovers expiring unused	$ 290,000,000
Operating loss carryforwards	$ 92,700,000
Federal [Member] \| Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration year	2017
Federal [Member] \| Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration year	2035
State [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 1,200,000
State [Member] \| Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration year	2016
State [Member] \| Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration year	2035

Income Taxes (Schedule Of Provision For Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Federal	$ (2,529,455)	$ (894,506)
State and local	169,266	(1,582,500)
Total deferred income tax expense (benefit)	(2,360,189)	(2,477,006)
Valuation allowance	2,360,189	2,477,006
Income tax benefit

Income Taxes (Schedule Of Reconciliation Of Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
U.S. statutory income tax rate	34.00%	34.00%
State and local taxes, net of federal tax benefit	1.90%	2.40%
Permanent differences between book and tax	5.60%	17.10%
Deferred tax adjustments	(9.30%)	(71.90%)
State rate adjustments	(0.10%)	(29.20%)
Valuation allowance	(32.10%)	47.60%
Effective income tax rate

Income Taxes (Schedule Of Components Of Deferred Tax Asset) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Current accruals	$ 1,687,951	$ 1,416,823
Deferred revenue	269,797
Depreciation and amortization	2,269,341	2,302,685
Deferred compensation	1,389,832	1,589,935
Net operating loss carryovers	32,744,557	30,246,136
Deferred tax assets	38,361,478	35,555,579
Valuation allowance	(37,912,693)	(35,555,579)
Net deferred tax assets before deferred tax liabilities	448,785
Accounting method changes	(448,785)
Net deferred tax assets

Net Loss Per Share (Schedule Of Computation Of Basic And Diluted Earnings Per Share) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Net Loss Per Share [Abstract]
Numerator for basic EPS	$ (7,352,775)	$ (5,202,441)
Numerator for diluted EPS	$ (7,352,775)	$ (5,202,441)
Denominator for basic EPS-weighted average shares	21,113,203	19,945,038
Denominator for diluted EPS	21,113,203	19,945,038
Basic EPS	$ (0.35)	$ (0.26)
Diluted EPS	$ (0.35)	$ (0.26)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Net Loss Per Share (Schedule Of Anti-Dilutive Securities Excluded From Computation Of Diluted Earnings Per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	3,578,867	3,382,780
Stock Options And Stock Appreciation Rights [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	706,494	487,146
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	752,008	697,751
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	2,120,365	2,197,883

Employee Benefit Plan (Details)	12 Months Ended
Employee Benefit Plan (Details)	Dec. 31, 2015
Empoyee Benefit Plan [Abstract]
Employer match of employee contributions	0.00%

Product Warranty Provisions (Details) - USD ($)	12 Months Ended
Product Warranty Provisions (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Product Warranty Provisions [Abstract]
Standard product warranty, coverage term	1 year
Warranty accrual, beginning of the fiscal period	$ 364,548	$ 501,212
Accrual adjustment for product warranty	171,384	84,402
Payments made	(219,097)	(221,066)
Warranty accrual, end of the fiscal period	$ 316,835	$ 364,548

Segment Information (Details) - USD ($)	12 Months Ended
Segment Information (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Total revenue	$ 37,674,524	$ 35,011,276
United States [Member]
Total revenue	19,757,986	21,626,788
International [Member]
Total revenue	$ 17,916,538	$ 13,384,488

Valuation And Qualifying Accounts (Details) - USD ($)	12 Months Ended
Valuation And Qualifying Accounts (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Allowance For Doubtful Accounts And Returns [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	$ 131,464	$ 383,077
Additions Charged to Cost and Expenses	(9,463)	48,742
Deductions	(28,523)	(300,355)
Balance at the End of Year	93,478	131,464
Allowance For Inventories Valuation [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	59,634	80,213
Additions Charged to Cost and Expenses	42,258	6,970
Deductions	(81,921)	(27,549)
Balance at the End of Year	$ 19,971	$ 59,634